Evidence map›Paper›PMID 33869753›Full record

ArticleLaryngoscope investigative otolaryngology2021

Treatment of head and neck carcinoma of unknown primary: Cracking a nut with a sledgehammer?

Diako Berzenji, Dominiek A Monserez, Gerda M Verduijn, Emilie A C Dronkers, Peter P Jansen, Stijn Keereweer, Aniel Sewnaik, Robert J Baatenburg de Jong, Jose A Hardillo

Abstract read
In one paragraph

Article in Laryngoscope investigative otolaryngology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Diako BerzenjiDepartment of Otorhinolaryngology and Head and Neck Surgery Erasmus University Medical Center Rotterdam The Netherlands.ORCID https://orcid.org/0000-0002-5281-735X
Dominiek A MonserezDepartment of Otorhinolaryngology and Head and Neck Surgery Erasmus University Medical Center Rotterdam The Netherlands.
Gerda M VerduijnDepartment of Radiation Oncology Erasmus University Medical Center Rotterdam The Netherlands.
Emilie A C DronkersDepartment of Otorhinolaryngology and Head and Neck Surgery Erasmus University Medical Center Rotterdam The Netherlands.ORCID https://orcid.org/0000-0003-1238-0613
Peter P JansenDepartment of Radiation Oncology Erasmus University Medical Center Rotterdam The Netherlands.
Stijn KeereweerDepartment of Otorhinolaryngology and Head and Neck Surgery Erasmus University Medical Center Rotterdam The Netherlands.
Aniel SewnaikDepartment of Otorhinolaryngology and Head and Neck Surgery Erasmus University Medical Center Rotterdam The Netherlands.
Robert J Baatenburg de JongDepartment of Otorhinolaryngology and Head and Neck Surgery Erasmus University Medical Center Rotterdam The Netherlands.
Jose A HardilloDepartment of Otorhinolaryngology and Head and Neck Surgery Erasmus University Medical Center Rotterdam The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare the impact on survival and late radiation toxicity of patients with squamous cell carcinoma of unknown primary who were treated with ipsilateral neck dissection and ipsilateral postoperative radiotherapy (PORT) and patients treated with ipsilateral neck dissection and PORT to both sides of the neck plus the pharyngeal axis.

methodsRetrospective cohort study performed at the Erasmus University Medical Center in which 78 patients with squamous cell carcinoma of unknown primary were identified. Thirty-nine patients received PORT to both sides of the neck plus the pharyngeal axis (BILAX) and another 39 patients were irradiated on the ipsilateral neck (IPSI) only. The endpoints of the present study were 3-year overall survival (OS), 3-year disease-free survival (DFS), and overall late radiation toxicity.

resultsThe 3-year OS rate of the entire group of 78 patients was 74.2% and the 3-year DFS rate was 72.7%. The 3-year OS rates for the IPSI and the BILAX groups were 74.4% and 74.1%, respectively (

conclusionThere was no significant difference in OS and DFS rates between the IPSI and the BILAX group. Late radiation toxicity was significantly higher in the BILAX group. LEVEL OF EVIDENCE: Level 2b: Individual retrospective cohort study.

Indexed as

cancer of unknown primaryhead and neck carcinomapharyngeal axisradiation toxicityradiotherapy

Identifiers

PMID33869753
PMCPMC8035952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.